Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aquaporin-10 (AQP10) is a member of the aquaglyceroporin subgroup of the aquaporin family of membrane transport proteins. It is primarily expressed in the small intestine and adipose tissue. AQP10 functions as a channel facilitating the transport of water, glycerol, and small neutral solutes, with unique pH-dependent gating regulating glycerol permeability in human adipocytes. Dysfunction or modulation of AQP10 has been identified as relevant to fat metabolism, particularly by mediating glycerol release during lipolysis, and may present a novel therapeutic target for obesity and related metabolic diseases. In the gastrointestinal tract, AQP10 may contribute to fluid and nutrient balance, though its specific roles in pathology are less well-studied compared to other aquaporins. No direct drugs or biomarkers are clinically established, but its structure-function relationship suggests therapeutic interest in metabolic regulation.
(No approved agents) Possible mechanism would be modulation (inhibition or activation) of AQP10-mediated glycerol and water transport, for example, openers of the pH-dependent glycerol gate to enhance glycerol efflux as an anti-obesity strategy
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aquaporin-10 (AQP10).